This is a Phase 1 study is to visualize biodistribution of a PET tracer called [18F]F-AraG (VisAcT) in cancer patients expected to undergo immunotherapy.
Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG (VisAcT), a Positron Emission Tomography Tracer for Imaging the Activation of the Immune System in Cancer Patients Expected to Undergo Immunotherapy
This is an exploratory Phase 1, prospective study assessing the biodistribution and radiation dosimetry of the Positron Emission Tomography [18F]FAraG (VisAcT) in cancer patients selected for immunotherapy. Each patient may have up to two [ 18F]FAraG PET imaging sessions, a baseline image and a post start of immunotherapy image. For each imaging session, patients will receive a single injection of [ 18F]FAraG and undergo up to four whole-body PET scans in the same day. Blood samples may be collected at up to 9 time points post-injection to analyze whole-blood/plasma time activity of [18F]FAraG. Following each imaging session, we will also assess safety in each subject. Blood pressure, heart rate, pulse oximetry, temperature, and respiratory count measurements as well as an electrocardiogram (ECG) recording will be taken prior to imaging, and after whole-body PET scans are completed.
You can join if…
Open to people ages 18–65
Cancer patients with identified tumor mass
Cancer patients expected to undergo immunotherapy
You CAN'T join if...
Under the age of 18
Women who are breastfeeding
Individuals with known or suspected substance abuse
Individuals unable or unwilling to comply with the study procedures
Patients currently receiving immunotherapy treatment
UCSF Imaging Center at China Basinaccepting new patients San Francisco, California, 94107, United States